Clinical burden of late-onset, clinically significant CMV infection beyond 100 days in allo-HSCT patients after letermovir prophylaxis. (PubMed, Curr Med Res Opin) - Apr 1, 2025 - "This study demonstrates the great burden of late-onset cs-CMVi in patients after allo-HSCT. Extended LET prophylaxis beyond 100 days post-transplant may benefit especially those at high risk of cs-CMVi."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Junko Hattori; Rika Ohkubo
|